Related references
Note: Only part of the references are listed.Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L. Piekarz et al.
BLOOD (2011)
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:: report from the International Peripheral T-Cell Lymphoma Project
Kerry J. Savage et al.
BLOOD (2008)
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma - A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)
M Crump et al.
CANCER (2004)
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
KJ Savage et al.
ANNALS OF ONCOLOGY (2004)